GIP-Only Agonists: The Next Mechanistic Wave

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Retatrutide (LY3437943) is a triple agonist targeting GLP-1, GIP, and glucagon receptors, showing significant reductions in A1C and weight in Phase 3 trials for type 2 diabetes Lilly's Retatrutide Phase 3 Trial Results.
Orforglipron, an oral GLP-1, helped participants maintain weight loss after switching from injectable incretins, retaining all but 0.9 kg of previously lost weight on average.
Clinical trials, such as NCT05929066 for retatrutide, are actively studying these new treatments for obesity or overweight ClinicalTrials.gov Retatrutide Study Details.
Orforglipron delivered weight loss of up to an average of 27.3 lbs in one of its pivotal Phase 3 trials in adults with obesity.

The landscape of treatments for type 2 diabetes and obesity is rapidly evolving, moving beyond single-target GLP-1 medications to embrace more complex mechanisms. A new wave of therapies, including GIP-only agonists and multi-agonists like retatrutide, are showing promising results in clinical trials. Retatrutide, a triple agonist, has already demonstrated significant reductions in A1C and weight in its first Phase 3 trial for type 2 diabetes. Meanwhile, orforglipron, an oral GLP-1 receptor agonist, offers a convenient alternative to injectables and has shown impressive weight loss results, with participants losing up to an average of 27.3 lbs in pivotal Phase 3 trials for adults with obesity. These advancements suggest a future where treatment options are more tailored and effective, addressing the multifaceted nature of metabolic disorders.

What are GIP-Only Agonists?

GIP-only agonists are a new class of medications that specifically target the glucose-dependent insulinotropic polypeptide (GIP) receptor in the body. GIP is a natural hormone, an incretin, which plays a crucial role in how our bodies manage blood sugar and process energy. When we eat, GIP is released from the gut, signaling the pancreas to release insulin, especially when blood sugar levels are high. This hormone also influences fat metabolism and energy balance. For many years, the focus in treating type 2 diabetes and obesity has been on glucagon-like peptide-1 (GLP-1) agonists, which are well-established for their ability to lower blood sugar and promote weight loss. However, research into GIP has revealed its distinct and complementary roles in metabolism, paving the way for drugs that specifically activate GIP receptors.

Understanding GIP's Role

GIP is one of the key incretin hormones. These hormones are released after eating and help to regulate blood glucose levels. While GLP-1 primarily slows gastric emptying, reduces appetite, and stimulates insulin secretion, GIP also contributes to insulin secretion in a glucose-dependent manner. This means GIP helps the body produce more insulin only when blood sugar levels are elevated, reducing the risk of hypoglycemia. Beyond its effects on insulin, GIP receptors are found in various tissues, including fat cells, which suggests a broader role in energy storage and metabolism. By activating these specific GIP receptors, GIP-only agonists aim to harness these natural physiological pathways to improve glucose control and influence weight.

The Evolution of Incretin-Based Therapies

The journey to GIP-only agonists builds upon decades of research into incretin biology. Early medications focused on GLP-1, leading to successful treatments for type 2 diabetes and, more recently, obesity. Medications like semaglutide and liraglutide are well-known GLP-1 receptor agonists. The next step involved combining the actions of GLP-1 and GIP, as seen in dual agonists like tirzepatide. These dual agonists activate both GLP-1 and GIP receptors, aiming for a more comprehensive metabolic effect. The concept of a "GIP-only" agonist, while not explicitly detailed in the provided research as a standalone drug in late-stage development, represents a mechanistic wave where scientists explore the unique benefits of targeting GIP individually. This exploration could lead to therapies with distinct advantages or applications, potentially offering a different side effect profile or specific benefits for certain patient populations. The ongoing development of various incretin-based therapies highlights a continuous effort to refine treatments for complex metabolic conditions.

Distinguishing GIP-Only from Multi-Agonists

For the full picture on the leading triple agonist, see our complete retatrutide evidence review. It is important to differentiate between GIP-only agonists and multi-agonists. While a GIP-only agonist would specifically target only the GIP receptor, multi-agonists, such as the triple agonist retatrutide, engage multiple receptors simultaneously. Retatrutide, for instance, activates GLP-1, GIP, and glucagon receptors. This multi-target approach aims to leverage the synergistic effects of these different hormonal pathways. The specific benefits of a GIP-only approach might include a more targeted action, potentially with fewer off-target effects, or a unique metabolic signature that could be advantageous for certain individuals. The development of GIP-only agents would represent a focused strategy, distinct from the broader, more potent effects often seen with multi-agonists. Researchers continue to investigate the optimal combination and individual targeting of incretin hormones to maximize therapeutic benefits for patients struggling with obesity and type 2 diabetes.

How Do Triple Agonists Like Retatrutide Work?

Triple agonists like retatrutide (LY3437943) operate by activating three different hormonal receptors: GLP-1, GIP, and glucagon. This multi-faceted approach is designed to provide a more comprehensive impact on blood sugar regulation, appetite control, and overall metabolism compared to medications that target only one or two of these pathways. Eli Lilly and Company is at the forefront of developing retatrutide, with ongoing clinical trials exploring its potential as a treatment for conditions like type 2 diabetes and obesity. The drug's mechanism aims to leverage the combined power of these three incretin hormones, which naturally play significant roles in the body's metabolic processes.

The Synergy of Three Receptors

The body naturally produces GLP-1, GIP, and glucagon, each contributing to metabolic health in unique ways. GLP-1 and GIP are both incretin hormones that stimulate insulin release in a glucose-dependent manner, meaning they help the pancreas produce more insulin when blood sugar is high. GLP-1 also slows down stomach emptying and reduces appetite, contributing to weight loss. GIP, in addition to stimulating insulin, also influences fat metabolism. Glucagon, typically known for raising blood sugar, also has receptors in the brain and other tissues where its activation can lead to increased energy expenditure and further weight loss. By activating all three receptors simultaneously, retatrutide aims to create a powerful synergistic effect. This combined action is expected to lead to more pronounced reductions in blood sugar (A1C) and body weight than what might be achieved with single or dual agonists.

Impact on Blood Sugar and Weight

The combined activation of GLP-1, GIP, and glucagon receptors by retatrutide results in several beneficial metabolic changes. For blood sugar control, the GLP-1 and GIP components enhance insulin secretion when needed, while the glucagon component might improve glucose utilization. For weight management, GLP-1 and GIP contribute to reduced appetite and increased satiety, helping individuals eat less. The glucagon component is thought to further boost energy expenditure, essentially helping the body burn more calories. This comprehensive approach has shown impressive results in early studies. In its first Phase 3 trial for the treatment of type 2 diabetes, retatrutide demonstrated significant reductions in A1C and weight Lilly's Retatrutide Phase 3 Trial Results. This finding underscores the potential of triple agonists to offer superior outcomes for patients struggling with both conditions. The breadth of these effects suggests that triple agonists could become a cornerstone in managing complex metabolic diseases.

Development by Eli Lilly and Company

Eli Lilly and Company is actively developing retatrutide as part of its expanding portfolio of incretin-based therapies. The company is investing significantly in understanding and harnessing the power of these hormonal pathways to address unmet medical needs in diabetes and obesity. The progress of retatrutide through clinical trials reflects a strategic push to innovate beyond existing treatments. The successful completion of its first Phase 3 trial for type 2 diabetes marks a critical milestone in bringing this novel medication closer to patients. "Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes," according to Eli Lilly and Company. This statement highlights the promising nature of this triple agonist. Further research and additional trials are ongoing to fully characterize its benefits, safety profile, and potential applications across various patient populations. The commitment to developing such advanced therapies indicates a future where treatment options are more potent and precisely targeted.

What Are the Latest Clinical Trial Findings for Retatrutide?

The latest clinical trial findings for retatrutide (LY3437943) show significant progress, particularly in its Phase 3 development for both type 2 diabetes and obesity. A key study, identified as NCT05929066, is currently active and focused on evaluating retatrutide in participants who have obesity or are overweight ClinicalTrials.gov Retatrutide Study Details. This trial represents a crucial step in understanding the full potential of this triple agonist beyond its initial success in diabetes management. The ongoing research aims to gather comprehensive data on its effectiveness and safety in a broader population.

Focus of the Phase 3 Trial (NCT05929066)

The Phase 3 trial with identifier NCT05929066 is designed to rigorously assess retatrutide in individuals living with obesity or overweight. Phase 3 trials are typically large-scale studies that compare the new treatment to existing therapies or a placebo, gathering extensive data on efficacy and safety before regulatory submission. For retatrutide, this particular trial is crucial for establishing its role as a potential standalone treatment for weight management. Participants in such studies are carefully selected based on specific eligibility criteria, which may include age, body mass index (BMI), and general health status. The primary goals often involve measuring changes in body weight over a specified period, as well as monitoring for any adverse events.

Participant Recruitment and Study Design

The study NCT05929066 is actively recruiting participants, indicating that it is in the process of enrolling individuals who meet the criteria for obesity or overweight. Clinical trials like this are meticulously designed to ensure scientific rigor and patient safety. They often involve multiple arms, where different groups receive varying doses of the investigational drug, a placebo, or an active comparator. The allocation of participants to these arms is typically randomized to minimize bias. Data collected at the beginning of the study, known as baseline characteristics, include demographics such as age, sex, race, and ethnicity, along with study-specific measures like initial weight. This comprehensive data collection allows researchers to evaluate the drug's effects across diverse groups and to understand any potential differences in response.

Measuring Efficacy and Safety

In the context of the NCT05929066 trial, efficacy endpoints would primarily focus on weight loss. This could involve measuring the percentage change in body weight from baseline, or the proportion of participants achieving specific weight loss thresholds (e.g., 5%, 10%, or 15% body weight reduction). Safety is equally paramount in Phase 3 trials. Researchers closely monitor for any adverse events, which are unfavorable changes in a participant's health that occur during or after the study. These can range from mild side effects to more serious health issues. The trial also collects data on abnormal laboratory findings. All-cause mortality, a measure of all deaths due to any cause, is also tracked during the study period. The comprehensive evaluation of both efficacy and safety is essential for determining if retatrutide is a viable and safe option for people with obesity or overweight. The results from this Phase 3 trial will be pivotal in shaping the future availability and use of retatrutide.

How Does Oral GLP-1 Therapy Compare to Injectable Options?

Oral GLP-1 therapy, exemplified by medications like orforglipron, offers a significant and convenient alternative to the injectable GLP-1 medications that have been the standard for years. The primary difference lies in the method of administration: oral medications are taken by mouth, while injectables require self-administration via a syringe. This distinction has profound implications for patient preference, adherence, and overall accessibility to treatment. Orforglipron is an oral small-molecule GLP-1 receptor agonist, representing a major advancement in making these effective therapies more patient-friendly.

The Convenience Factor of Oral Medications

The most apparent advantage of oral GLP-1 therapy is its convenience. For many patients, the prospect of daily or weekly injections can be a barrier to starting or continuing treatment. Oral pills eliminate the need for needles, making the treatment regimen simpler and potentially less intimidating. This ease of use can significantly improve patient adherence, meaning people are more likely to take their medication as prescribed, leading to better health outcomes. For conditions like obesity and type 2 diabetes, which require long-term management, a convenient oral option can be a game-changer. Eli Lilly has recognized this need and has submitted orforglipron to the U.S. Food and Drug Administration for the treatment of obesity, signaling its potential widespread availability. "Lilly has submitted orforglipron to the U.S. Food and Drug Administration for the treatment of obesity," stated Eli Lilly and Company, emphasizing the importance of this oral formulation.

Maintaining Weight Loss with Oral Therapy

One of the critical challenges in weight management is sustaining weight loss over time. Oral GLP-1 therapies like orforglipron have shown promise in this area. In a first-of-its-kind Phase 3 trial, orforglipron helped people maintain weight loss even after switching from injectable incretins, such as Wegovy or Zepbound. This trial specifically evaluated how well patients could preserve their weight loss when transitioning to an oral medication. The results were highly encouraging: participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average Lilly's Orforglipron Phase 3 Transition Trial. This demonstrates that oral options can be just as effective in long-term weight maintenance as their injectable counterparts, providing a flexible and sustainable treatment path.

Efficacy and Safety Profile

Beyond convenience, the efficacy and safety of oral GLP-1 therapies are paramount. Orforglipron has delivered substantial weight loss results in its pivotal Phase 3 trials. In one of these trials, adults with obesity experienced weight loss of up to an average of 27.3 lbs Lilly's Orforglipron Weight Loss Data. This level of weight reduction is comparable to what has been observed with some of the most effective injectable GLP-1 medications. The safety profile of orforglipron has also been consistent with injectable GLP-1 medicines, meaning it generally exhibits similar types of side effects, which often include gastrointestinal issues like nausea, vomiting, and diarrhea. These findings suggest that oral GLP-1 agonists can offer comparable benefits to injectables without sacrificing efficacy or introducing new significant safety concerns. The development of such effective oral options broadens the appeal of incretin-based therapies to a wider patient population.

What Are the Safety and Efficacy Results for Orforglipron?

Orforglipron has demonstrated robust safety and efficacy results in its Phase 3 clinical trials, marking it as a significant contender in the treatment of obesity and type 2 diabetes. The medication has achieved statistically significant efficacy, meaning its positive effects on weight loss and metabolic parameters were clearly measurable and unlikely due to chance. Importantly, its safety profile has been found to be consistent with what is typically observed with injectable GLP-1 medicines, providing reassurance about its tolerability.

Statistically Significant Efficacy

The efficacy of orforglipron has been a key highlight of its clinical development. In its successful Phase 3 trials, orforglipron demonstrated statistically significant efficacy results Orforglipron Oral GLP-1 Phase 3 Trial Data. This means that the observed improvements in patient outcomes, such as weight loss and potentially blood sugar control (though the primary focus here is obesity), were not just random fluctuations but genuine effects of the medication. For adults with obesity, one pivotal Phase 3 trial showed weight loss of up to an average of 27.3 lbs. This level of weight reduction is clinically meaningful and suggests that orforglipron can be a powerful tool in combating obesity. The consistent positive outcomes across multiple trials reinforce the drug's potential to make a substantial difference in patient health.

Consistent Safety Profile

A crucial aspect of any new medication is its safety profile. Orforglipron's safety profile has been consistent with that of existing injectable GLP-1 medicines. This is an important finding because it indicates that patients can expect similar types of side effects, which are generally well-understood and manageable. Common side effects associated with GLP-1 agonists, both oral and injectable, often involve the gastrointestinal system, such as nausea, vomiting, diarrhea, or constipation. These side effects are usually mild to moderate and tend to decrease over time as the body adjusts to the medication. The consistency in safety profiles suggests that the oral formulation does not introduce new or unexpected risks compared to the established injectable versions. This predictability in safety is a major advantage for both patients and healthcare providers when considering treatment options.

Promise for Long-Term Weight Management

The results from orforglipron's trials offer great promise for long-term weight management. The ability of the drug to help participants maintain weight loss after switching from injectable incretins is particularly encouraging. In one trial, individuals who transitioned to orforglipron from medications like Wegovy were able to maintain all but 0.9 kg of their previously achieved weight loss on average. This indicates that orforglipron can serve as a sustainable option for patients who have already achieved weight loss and are looking for a convenient way to keep it off. Long-term weight management is critical for improving overall health outcomes and reducing the risk of obesity-related complications. The oral nature of orforglipron further enhances its potential for sustained use, making it easier for patients to adhere to their treatment plan over many years. A publication detailing the findings on orforglipron for obesity treatment is expected in November 2025, further solidifying the evidence base for this promising therapy Orforglipron Publication Details.

What Does the Future Hold for GIP-Only and Multi-Agonists?

The future for GIP-only and multi-agonists in the treatment of metabolic conditions like obesity and type 2 diabetes appears very promising. These new classes of medications represent the next generation of pharmacological interventions, moving beyond the single-target approach of earlier GLP-1 drugs. Our next-gen GLP-1 pipeline landscape maps the trials, timelines, and mechanisms in one view. The development pipeline, particularly from companies like Eli Lilly, is rich with innovative compounds designed to offer improved efficacy and potentially more convenient administration methods. This evolutionary step is driven by a deeper understanding of the complex interplay between various hormones in regulating metabolism.

Enhanced Weight Loss and Blood Sugar Control

The primary promise of GIP-only and multi-agonists is their potential to offer even greater benefits in terms of weight loss and blood sugar control compared to existing treatments. By targeting multiple hormonal pathways, these drugs aim to create a more powerful and comprehensive metabolic response. For example, retatrutide, a triple agonist, has already shown significant reductions in A1C and weight in its first Phase 3 trial for type 2 diabetes. This demonstrates that activating GLP-1, GIP, and glucagon receptors concurrently can lead to superior outcomes. Similarly, orforglipron, an oral GLP-1 receptor agonist, has delivered impressive weight loss, with adults with obesity achieving an average reduction of up to 27.3 lbs in pivotal Phase 3 trials. These results suggest that future treatments will be more effective, helping a larger proportion of patients achieve their health goals.

Broader Patient Accessibility and Preference

The introduction of oral formulations, such as orforglipron, is a major step towards broader patient accessibility and improved treatment adherence. Many individuals prefer oral medications over injectables due to convenience and a dislike of needles. The fact that orforglipron helped people maintain weight loss after switching from injectable incretins, retaining all but 0.9 kg of their previously achieved weight loss on average, highlights its potential to serve as a sustainable long-term option. This shift toward more patient-friendly administration methods will likely increase the overall uptake of these highly effective therapies. As more oral options become available, patients will have greater flexibility and choice, making it easier for them to commit to and sustain their treatment plans over many years.

Ongoing Research and Development

The field of metabolic medicine is characterized by continuous innovation, and the development of GIP-only and multi-agonists is a testament to this. Pharmaceutical companies are investing heavily in research to identify new targets and refine existing ones. Clinical trials, such as the ongoing Phase 3 study of retatrutide (NCT05929066) for obesity or overweight, are crucial for gathering the necessary data on efficacy, safety, and long-term outcomes. These studies will define the full potential of these new medications and determine their optimal use in various patient populations. The information from these trials will also help in understanding any differential effects or specific benefits that GIP-only agonists might offer compared to multi-agonists. The future will likely see a diverse array of incretin-based therapies, allowing healthcare providers to tailor treatments more precisely to individual patient needs and preferences.

Frequently Asked Questions

What is a GIP-only agonist?

A GIP-only agonist is a type of medication that specifically activates the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is a natural hormone that helps regulate blood sugar by stimulating insulin release when glucose levels are high. While the provided research focuses on multi-agonists and oral GLP-1s, the concept of a GIP-only agonist represents a focused approach to harness GIP's unique metabolic roles, which include effects on fat metabolism and energy balance.

How does a triple agonist like retatrutide differ from a GLP-1 agonist?

A triple agonist like retatrutide differs significantly from a GLP-1 agonist because it activates three different receptors: GLP-1, GIP, and glucagon. In contrast, a GLP-1 agonist targets only the GLP-1 receptor. This multi-target approach of retatrutide is designed to provide a more comprehensive impact on blood sugar control and weight reduction. In its first Phase 3 trial for type 2 diabetes, retatrutide demonstrated significant reductions in both A1C and weight.

Is orforglipron approved for weight loss yet?

Eli Lilly has submitted orforglipron to the U.S. Food and Drug Administration for the treatment of obesity. This means the drug is currently undergoing review by the FDA. While it has shown promising results in Phase 3 trials, delivering weight loss of up to an average of 27.3 lbs in adults with obesity, it is not yet officially approved for weight loss. Regulatory approval will depend on the FDA's assessment of the submitted data.

What are the main benefits of oral GLP-1 medications?

The main benefits of oral GLP-1 medications, such as orforglipron, include increased convenience and improved patient adherence compared to injectable options. Oral medications eliminate the need for needles, making them a more appealing option for many patients. Orforglipron has also demonstrated strong efficacy, helping participants maintain all but 0.9 kg of their previously achieved weight loss after switching from injectable incretins.

Where can I find more information about ongoing clinical trials for these new drugs?

You can find more information about ongoing clinical trials for new drugs like retatrutide by visiting official clinical trial registries. For example, details about the study of retatrutide (LY3437943) in participants who have obesity or are overweight can be found under the study identifier NCT05929066 on ClinicalTrials.gov. These sites provide comprehensive information on study design, eligibility criteria, and progress.